NAD+ Precursors and Infusions: Cellular Biology, Evidence and Safety

Nicotinamide adenine dinucleotide (NAD⁺) is a fundamental coenzyme found in every living cell, essential for cellular bioenergetics, mitochondrial ATP production, and DNA repair. Over the last decade, geroscience research has established that intracellular NAD⁺ concentrations decline precipitously during chronological aging—dropping by an estimated 40% to 60% by mid-adulthood.

This age-related depletion impairs the activity of critical NAD⁺-dependent protective enzymes, notably sirtuins (epigenetic regulators and metabolic sensors) and poly(ADP-ribose) polymerases (PARPs) (vital for genomic DNA repair).

The commercial health and longevity market has responded with an array of therapies claiming to restore youth-level cellular NAD⁺: from oral dietary precursors like nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR), to high-dose intravenous (IV) NAD⁺ infusions and subcutaneous injections.

However, cellular delivery of NAD⁺ is biologically complex. This article reviews the biochemistry of the NAD⁺ salvage pathway, evaluates human clinical trial evidence for oral precursors versus IV infusions, explores the primary culprit behind NAD⁺ degradation (the CD38 enzyme), and highlights practical safety considerations.

Key takeaways

Essential Coenzyme and Consumed Substrate: NAD⁺ functions in two distinct biological roles: as a reversible electron carrier (NAD⁺ ↔NADH) in mitochondrial glycolysis and the Krebs cycle, and as an irrevocably consumed signaling substrate for sirtuins (SIRT1–SIRT7), PARP1, and CD38.
The Delivery Paradox: Intact NAD⁺ is a large, charged dinucleotide molecule (~663 Da) with two phosphate groups, preventing it from crossing intact mammalian cell membranes directly via simple diffusion. In the gut, oral NAD⁺ is rapidly hydrolyzed into smaller precursors before systemic absorption.
Oral Precursors (NR and NMN): Clinical trials in humans confirm that oral nicotinamide riboside (NR) and nicotinamide mononucleotide (NMN) are well tolerated and reliably increase whole-blood NAD⁺ levels by 40% to 100% within 2 to 4 weeks. However, clinical evidence showing that this translates to extended human lifespan or functional disease reversal remains preliminary.
Intravenous (IV) Infusions: IV NAD⁺ bypasses the digestive tract and elevates plasma NAD⁺ and its breakdown products rapidly, but infusions trigger acute, uncomfortable adverse symptoms (intense chest tightness, gastrointestinal cramping, flushing, nausea) driven by adenosine receptor activation.
The CD38 Degradation Barrier: Age-related NAD⁺ depletion is not primarily caused by a failure of cellular synthesis, but by rampant enzymatic degradation driven by the pro-inflammatory ecto-enzyme CD38, which is upregulated in aging tissues by senescent cell secretomes (SASP).

Biochemical Roles: Energy Carrier vs Consumed Signaling Substrate

In cellular biochemistry, NAD⁺ performs two fundamentally different functions:

                                 NAD+ Functions
                                       │
         ┌─────────────────────────────┴─────────────────────────────┐
         ▼                                                           ▼
Coenzyme Redox Reactions                                   Enzymatic Consumption
($NAD^+ \leftrightarrow NADH$)                         (Degraded to Nicotinamide)
• Glycolysis (Cytoplasm)                                • Sirtuins (SIRT1-7: Epigenetic repair)
• Krebs TCA Cycle (Mitochondria)                        • PARP1 (Genomic DNA strand break repair)
• Electron Transport Chain (ATP production)             • CD38 / CD157 (Immune signaling & degradation)
[ Reversibly Cycled — Not Lost ]                        [ Irrevocably Destroyed — Must Be Re-synthesized ]

1. Metabolic Redox Cycling (Reversible)

In intermediary metabolism, NAD⁺ accepts hydride ions to become reduced NADH. NADH then transfers these electrons to Complex I of the mitochondrial respiratory chain to drive oxidative phosphorylation, generating ATP, and is oxidized back to NAD⁺. In this pathway, NAD⁺ molecules are not destroyed; they cycle continuously back and forth thousands of times per minute.

2. Consumptive Signaling Reactions (Irreversible Breakdown)

In contrast, when regulatory enzymes use NAD⁺, they do not merely borrow electrons; they break the covalent glycosidic bond, cleaving the molecule into nicotinamide (NAM) and an ADP-ribose moiety:

Sirtuins (SIRT1–SIRT7): Deacetylate histones, transcription factors (PGC-1α, FOXO), and mitochondrial proteins, promoting mitochondrial biogenesis, antioxidant defense, and metabolic resilience.
PARPs (PARP1 and PARP2): Detect single-strand DNA breaks and use NAD⁺ to assemble poly(ADP-ribose) chains that recruit DNA repair machinery. In states of oxidative stress or UV exposure, PARP activation can consume over 80% of total intracellular NAD⁺ pools within minutes.
CD38: An ecto-enzyme on immune cells that consumes roughly 100 molecules of NAD⁺ for every single molecule of cyclic ADP-ribose it synthesizes.

Why Cellular NAD+ Declines with Age: The CD38 Pathway

For many years, scientists assumed that falling NAD⁺ levels in aging tissues reflected failing enzymatic synthesis. Groundbreaking research published in Cell Metabolism demonstrated the opposite: NAD⁺ synthesis capacity remains relatively intact, but enzymatic consumption explodes.

The primary culprit is CD38, a glycoprotein ecto-enzyme expressed primarily on macrophages and immune cells:

As tissues age, senescent cells accumulate and release a cocktail of pro-inflammatory cytokines (the senescence-associated secretory phenotype, SASP).
SASP factors (specifically IL-6, TNF-α, and IFN-γ) recruit resident macrophages and drive dramatic upregulation of CD38 expression.
Upregulated CD38 actively degrades extracellular NAD⁺ and its precursors (NMN) before they can enter parenchymal cells.
In animal models, knocking out the CD38 gene or inhibiting CD38 with small molecules preserves tissue NAD⁺ concentrations into old age and protects against metabolic dysfunction.

The NAD+ Salvage Pathway: Precursors Compared

Because de novo synthesis from dietary tryptophan (the kynurenine pathway) is slow and inefficient, cells rely primarily on the NAD⁺ salvage pathway to recycle nicotinamide:

                           The NAD+ Salvage Pathway
                                      │
               Nicotinamide (NAM) ◄───┴─── (Sirtuins, PARPs, CD38)
                       │
             [ NAMPT Enzyme (Rate-Limiting) ]
                       │
                       ▼
         Nicotinamide Mononucleotide (NMN) ◄──── Nicotinamide Riboside (NR)
                       │                              [ NRK Kinase ]
             [ NMNAT Enzyme ]
                       │
                       ▼
                      NAD+

The Contenders:

Nicotinamide Riboside (NR): A nucleoside consisting of nicotinamide linked to a ribose ring. It enters cells via equilibrative nucleoside transporters (ENTs) and is phosphorylated by nicotinamide riboside kinases (NRK1 and NRK2) directly to form NMN, which is then converted to NAD⁺.
Nicotinamide Mononucleotide (NMN): A nucleotide consisting of nicotinamide, ribose, and a 5′-phosphate group. While NMN was historically believed to require extracellular dephosphorylation to NR prior to cell entry, researchers identified a specific transporter (Slc12a8) in murine small intestine that can transport NMN directly across cell membranes.
Intact NAD+: Contains an additional adenosine monophosphate group. Intact NAD⁺ cannot easily cross plasma membranes without being dephosphorylated extracellularly by enzymes like CD73 to NMN or NR.

Oral Precursors (NR vs NMN): Human Clinical Evidence

Over the past five years, numerous double-blind, randomized, placebo-controlled clinical trials have evaluated oral NR and NMN in humans:

1. Nicotinamide Riboside (NR) Trials

Multiple published clinical studies (e.g. Martens et al., Nature Communications; Trammell et al.) confirm that oral NR (500 mg to 2000 mg daily) is safely tolerated and produces a dose-dependent, steady-state 40% to 90% increase in whole-blood NAD⁺.
In older adults, NR reduced systemic pro-inflammatory cytokines (IL-6, TNF-α) and lowered aortic stiffness, but produced modest or negligible effects on insulin sensitivity, mitochondrial respiration, and skeletal muscle strength.

2. Nicotinamide Mononucleotide (NMN) Trials

Clinical trials (e.g. Yoshino et al., Science 2021; Igarashi et al., npj Aging 2022) evaluated oral NMN (250 mg to 1000 mg daily) in middle-aged and older adults over 10 to 12 weeks.
In postmenopausal women with prediabetes, NMN significantly increased muscle insulin sensitivity (glucose disposal rate during hyperinsulinaemic-euglycemic clamps) and enhanced muscle remodeling gene expression.
A 2023 trial by Lin and colleagues demonstrated significant improvements in 6-minute walking test distance and subjective vitality scores in older adults receiving 600 mg daily.

Intravenous (IV) NAD+ Infusions: Science and Practical Realities

In commercial wellness and anti-aging clinics, intravenous NAD⁺ infusions (typically 250 mg to 1000 mg infused over 2 to 4 hours) have become widespread.

What Happens Pharmacokinetically During an IV Infusion?

A landmark human clinical pharmacokinetic study published by Grant and colleagues in Frontiers in Aging Neuroscience (2019) tracked plasma and urine metabolites during a constant 750 mg IV NAD⁺ infusion:

During the first 2 hours of infusion, no intact NAD⁺ or nicotinamide was excreted in the urine, and plasma NAD⁺ rose only marginally, indicating rapid tissue extraction and cellular binding.
After 2 hours, circulating levels of NAD⁺, nicotinamide, and methylated breakdown products (methylnicotinamide) spiked dramatically in plasma and urine.

Adverse Reactions During IV Infusion

Unlike oral precursors, intravenous NAD⁺ infusion provokes immediate, intense autonomic and physical side effects if infused at standard drip rates:

Chest Tightness and Constriction: Sensation of heavy pressure on the sternum.
Intense Abdominal Cramping and Nausea: Painful gut contractions and urge to defecate.
Flushing and Headache: Throbbing temporal headache and peripheral vasodilation.

Biological Cause: Extracellular NAD⁺ and its breakdown product adenosine stimulate purinergic adenosine A1 and A2A receptors on cardiac pacemaker cells, coronary vasculature, and intestinal smooth muscle. To tolerate an infusion, the drip rate must be set very slow, typically requiring 3 to 5 hours per session.

Subcutaneous and Intramuscular NAD+ Injections

Due to the length, cost, and discomfort of IV infusions, subcutaneous (SC) and intramuscular (IM) injections of sterile NAD⁺ solution (typically 50 mg to 100 mg per injection, such as the NovaMeds NAD+ 300 and 600 preparations) have gained substantial clinical use:

Pharmacokinetics: Subcutaneous injection allows slow, continuous systemic absorption from the subcutaneous capillary bed over several hours, avoiding the acute plasma spikes that trigger severe chest pressure during rapid IV delivery.
Local Discomfort: Subcutaneous injection frequently produces a localized, transient burning or stinging sensation at the injection site due to the acidic pH of concentrated NAD⁺ solutions. Injecting slowly and using room-temperature solution mitigates discomfort.
Research Status: While widely used in private clinical practice, large-scale randomized controlled trials directly comparing subcutaneous NAD⁺ injection against oral NMN/NR are still ongoing.

Safety Profile, Methylation Demands and Oncological Debates

1. The Methylation Pool Depletion (The MTHFR Link)

When high-dose NAD⁺ or its precursors enter cells and are cleaved by sirtuins or PARPs, large quantities of nicotinamide (NAM) are released.

To prevent high NAM concentrations from inhibiting sirtuins (via product inhibition), the body excretes excess NAM by methylating it into N-methylnicotinamide (MeNAM) via the liver enzyme nicotinamide N-methyltransferase (NNMT).
NNMT requires S-adenosylmethionine (SAMe) as the universal methyl donor.
Clinical Concern: Chronic mega-dosing of oral NAD⁺ precursors (e.g. >1000 mg daily) can deplete cellular methyl pools, potentially lowering choline, betaine, and elevating homocysteine. Many clinicians co-prescribe a methyl donor (such as trimethylglycine / TMG, 500 mg daily) alongside long-term NAD⁺ therapies.

2. The Theoretical Oncological Debate

Malignant tumor cells exhibit altered metabolism (the Warburg effect) and have high energy and DNA repair demands, making them voracious consumers of NAD⁺.

While extensive clinical and preclinical trials have shown that NAD⁺ precursors do not initiate de novo cancer, theoretical concerns remain that elevating systemic NAD⁺ could support the survival or resistance of existing, pre-diagnosed malignant tumors.
Patients with active, untreated malignancies are advised to avoid high-dose NAD⁺ supplementation.

Frequently Asked Questions

Is oral NMN legal to buy?

In late 2022, the US FDA determined that NMN could no longer be marketed as a dietary supplement in the United States because it was previously authorized for investigation as a new pharmaceutical drug (under an Investigational New Drug application). However, NMN remains widely sold in other international jurisdictions, and its physiological precursor, nicotinamide riboside (NR), remains fully permitted as a dietary supplement in both the US and Europe.

Can I just take high-dose niacin (vitamin B3) instead?

Standard niacin (nicotinic acid) can raise NAD⁺ via the Preiss-Handler pathway, but high doses (>1000 mg) trigger severe, uncomfortable cutaneous prostaglandin flushing and can cause hepatotoxicity, insulin resistance, and gout. Precursors like NR and NMN bypass the Preiss-Handler pathway and do not induce prostaglandin-mediated flushing.

Which is better: NMN or NR?

Both molecules are effective at raising human cellular NAD⁺ levels. In head-to-head clinical trials, both produce comparable increases in blood NAD⁺. Choice between them typically comes down to regional regulatory availability, formulation stability, and individual patient tolerance.

Scientific references

Cambronne ED, Kraus WL. Location, Location, Location: Compartmentalization of NAD+ Synthesis and Functions in Mammalian Cells. Trends in Biochemical Sciences. 2020;45(10):858-873. PubMed PMID: 32674966
Chini CCS, et al. The NADase CD38 is induced by factors secreted from senescent cells providing a potential link between senescence and age-related NAD+ decline. Nature Metabolism. 2020;2(11):1345-1359. PubMed PMID: 33199853
Grant R, et al. A Pilot Study Investigating Changes in the Human Plasma and Urine NAD+ Metabolome During a 6 Hour Intravenous Infusion of NAD+. Frontiers in Aging Neuroscience. 2019;11:257. PubMed PMID: 31551752
Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nature Communications. 2018;9(1):1286. PubMed PMID: 29599478
Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021;372(6547):1224-1229. PubMed PMID: 33888596

This article is educational and does not constitute personalized treatment advice. Treatment decisions depend on individual circumstances and professional assessment.